Weifa ASA : Information regarding the contemplated Offering in Vistin Pharma ASA
(Thomson Reuters ONE) -
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR
INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES
Oslo, Norway, 15 May 2015
Weifa ASA (OSE: WEIFA), reference is made to Weifa ASA's ("Weifa") announcement
on 20 April 2015 regarding the contemplated sale of Weifa's B2B business and
tablet production to the newly established company Vistin Pharma AS, and the
contemplated equity issue (the "Offering") in Vistin Pharma ASA (the "Company"
or "Vistin Pharma").
The Offering consists of two tranches;
* 15,554,935 new shares at NOK 10 per new share (the "New Shares") are
directed towards the shareholders of Weifa as of 19 May 2015 (the "Rights
Offering"), who are not resident in a jurisdiction where such offering would
be unlawful or would (in jurisdictions other than Norway) require any
prospectus filing, registration or similar action (the "Eligible
Shareholders"); and
* 1,500,000 new shares at NOK 10 per new share (the "Employee Offer Shares")
are directed towards the Company's employees, executive management and Board
of Directors (the "Employee Offering").
The last day of trading in the Weifa share including the right to receive
subscription rights in Vistin Pharma will be 19 May 2015. Each eligible
shareholder will be granted one subscription right for every 102 Weifa shares
owned as of 19 May 2015, as registered in the shareholder register in the VPS as
of the end of 21 May 2015. One subscription right will, subject to applicable
securities law, give the holder the right to subscribe for and be allocated one
(1) new share in the Company in the Rights Offering. Oversubscription is
allowed. Subscription without subscription rights is not permitted.
The Weifa share will trade exclusive the right to receive subscription rights
from and including 20 May 2015.
The subscription period in the Offering is expected to commence on 26 May 2015
at 09:00 CET and expire on 4 June 2015 at 16:30 CET. The trading period for the
subscription rights is expected to commence on 26 May 2015 at 09:00 and expire
on 2 June 2015 at 16:30 CET. All dates are subject to the approval of the
prospectus. Oslo Børs' resolution on whether to accept the Company's application
for listing of its shares on Oslo Axess is expected to be announced on 26 May
2015.
The allocation of shares is expected to take place on or about 5 June 2015 and
the listing and first day of trading of Vistin Pharma's shares on Oslo Axess is
expected to commence on or about 10 June 2015 (subject to approval of the
Company's listing application by the board of directors on the Oslo Stock
Exchange and the fulfilment of certain listing requirements).
Further information regarding the terms of the Offering will be published upon
approval of the Vistin Pharma prospectus.
Contact:
Kjell-Erik Nordby
CEO
+47 913 64 280
Kjell-erik.nordby(at)weifa.no
Gunnar Manum
CFO
+47 951 79 190
gunnar.manum(at)weifa.no
* * *
This press release does not constitute or form part of an offer or solicitation
to purchase or subscribe for securities in the United States. The securities
referred to herein may not be offered or sold in the United States absent
registration or an exemption from registration as provided in the U.S.
Securities Act of 1933, as amended. The Company does not intend to register any
portion of the offering of the securities in the United States or to conduct a
public offering of the securities in the United States. Copies of this
announcement are not being made and may not be distributed or sent into
Australia, Canada, Japan or the United States.
This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Weifa ASA via GlobeNewswire
[HUG#1921761]
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="TerraX announces Private Placement of $2.5 Million and sale of option on 1.0% NSR for $1 Million to Osisko; drills 14.09 m @ 2.96 g/t Au at Northbelt.
Datum: 15.05.2015 - 08:00 Uhr
Sprache: Deutsch
News-ID 393573
Anzahl Zeichen: 4918
contact information:
Town:
Oslo
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 160 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Weifa ASA : Information regarding the contemplated Offering in Vistin Pharma ASA"
steht unter der journalistisch-redaktionellen Verantwortung von
Weifa ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
